{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-311294","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.832556+00:00","generated_at":"2026-05-16T13:58:30.659870+00:00","sec_items":["5.07","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"JAGX stockholders approve three proposals; crofelemer MVID trial shows up to 37% PS reduction","bullets":["Stockholders approved proposal to issue shares upon exchange/redemption of Series N Preferred Stock (1,032,716 For, 73,065 Against).","Stockholders approved proposal to issue New PIPE Shares and Pre-Funded Warrant under Sept 28 securities purchase agreement (2,049,724 For).","Stockholders approved adjournment proposal (2,058,277 For).","Initial MVID proof-of-concept trial shows crofelemer can reduce total parenteral support by up to 37% in infants with microvillus inclusion disease.","Company met with FDA on Oct 2, 2025 for advice on expedited approval pathway for crofelemer for MVID; no approved treatments exist."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-311294","json":"https://secwatch.observer/filing/0001193125-25-311294.json","markdown":"https://secwatch.observer/filing/0001193125-25-311294.md","text":"https://secwatch.observer/filing/0001193125-25-311294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525311294/0001193125-25-311294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525311294/jagx-20251208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:58:30.659870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}